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SKIN CANCER SCREENING IN THE PRIMARY CARE SETTING  
EMILY ELIZABETH LEWANDOWSKI 
ABSTRACT 
Introduction   
Skin cancer is the most common cancer in the United States and melanoma is the fifth 
most common kind of cancer. The incidence of melanoma has been increasing over the 
past thirty years. This type of cancer can be detected using a visual skin examination. 
Survival is related to the thinness and stage at the time of diagnosis. Clinicians find 
thinner, earlier stage melanomas compared to those found by patients and significant 
others.  
Review of the Literature  
The average American visits their primary care provider twice annually and skin 
conditions are the number one reason Americans younger than sixty-five visit their 
primary care physician. However, the majority of residents in the United States are not 
comfortable with performing the full body skin examination required to screen for 
melanoma. Medical schools in the United States spend one percent of the curriculum on 
dermatologic conditions. In fact, the United States Preventative Services Task Force does 
not support regular skin cancer screening by primary care providers since there is limited 
evidence that primary care physicians perform adequate skin examinations.  
Methods 
This curriculum is aimed at teaching internal medicine and family medicine interns and 
primary care physician assistants and nurse practitioners the full body skin cancer 
	  	   vi 
screening examination as well as the ability to differentiate between benign and 
malignant skin lesions. A pre- and post-course examination of benign versus malignant 
lesions will be distributed and the scores will be analyzed using a paired T-test. A pre- 
and post-course Likert scale will be dispersed to evaluate how clinical practice changes 
based on this course. Mean and standard deviation for the overall Likert scale as well as 
individual parts of the scale will be calculated and a paired T-test will be used to analyze 
how the course changed clinical practice of the clinicians. Additionally, standardized 
patients will be provided for the participants to practice the full body skin examination. 
Conclusion 
This study is unique in that it is teaching primary care medical interns as well as 
physician assistants and nurse practitioners the full body skin examination. Limitations 
include a small sample size, voluntary participation in the setting of a busy work 
schedule, and pushback from clinicians since performing full body skin exams are not 
recommended at this time.  
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INTRODUCTION 
Background 
Skin cancer is the most common type cause of cancer in the United States of America1, 
and melanoma skin cancer is the fifth most common kind of cancer in the United States2. 
Unlike most cancers, the incidence and mortality of melanoma has been increasing over 
the past three decades2. The overall lifetime risk for the development of melanoma in the 
United States of America is one in fifty-two for men and one in seventy-seven for 
women2. In 2016, it was estimated that 76,400 people are diagnosed with melanoma and 
10,100 die of melanoma annually1. 
 Risk factors for the development of melanoma include age2, gender2, skin type3, 
immunocompromised state4, personal or family history of melanoma3, and presence of 
dysplastic nevi3. White men age sixty-five and older are at high risk of developing 
melanoma2. Ninety-eight percent of those who develop melanoma have at least one risk 
factor5.   
 Diagnosis of skin cancer involves direct visualization of skin. One of the most 
commonly taught skin cancer assessment techniques is the ABCDE mnemonic6. This 
technique involves looking for asymmetry, border irregularity, non-uniform color, 
diameter greater than six millimeters, and evolution of a skin lesion. Both patients and 
clinicians can use this mnemonic to identify potentially cancerous skin lesions; however, 
clinicians find significantly thinner skin cancers than those identified by the patient or a 
patient’s significant other7. 
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 Treatment and prognosis of skin cancer are related to the type of lesion as well as 
the stage at which the lesion is identified. Non-melanoma skin cancer typically does not 
result in significant morbidity or mortality1, but it is usually treated with surgical 
excision, Mohs micrographic surgery, radiation, curettage, and electrodessication to 
decrease the risk of metastasis8. The morbidity and mortality of melanoma is greater than 
that of non-melanoma skin cancer. Prognosis is related to the thickness of the lesion at 
diagnosis9. Early-stage melanoma is typically treated with surgery whereas metastatic 
melanoma requires a combination of chemotherapy, radiation therapy, and 
immunotherapy10. 
 
Statement of the Problem 
It has been shown that clinicians find significantly thinner lesions compared with the 
lesions found by the patient himself/herself or the patient’s significant other7; however, 
the vast majority of primary care residents (seventy-five percent) have never been trained 
in the full body skin examination11. In fact, almost three-quarters of medical students 
report that they are not skilled in performing a full body skin examination12. 
Only thirty-one percent of primary care providers perform skin examinations on all of 
their patients13 despite the fact that diagnosing melanoma at an earlier stage provides a 
significant survival benefit9.   
 In 2009, the United States Preventative Services Task Force stated that there was 
insufficient evidence to recommend skin cancer screening by primary care providers8. 
One of the cited arguments was insufficient evidence that primary care providers can 
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accurately diagnose melanoma8. There have been studies examining the difference 
between lesions identified by dermatologists and primary care providers. Dermatologists 
identified significantly thinner and earlier-stage melanomas compared with primary care 
providers14.  However, there is a shortage of dermatologists relative to the demand15 and 
the average American visits his or her primary care provider twice per year2. Therefore, 
primary care providers can act as the triage providers and refer suspicious lesions to 
dermatologists.  
 
Hypothesis 
Implementing a skin cancer screening curriculum for internal medicine and family 
medicine interns, physician assistants, and nurse practitioners will result in improved 
comfort in performing full body skin examinations and increased knowledge about what 
to do if a suspicious lesion is found on a patient. 
 
Objectives and specific aims 
The objective of implementing a skin cancer screening curriculum is for primary care 
providers to identify earlier stage, thinner skin cancers. Here, we will seek to integrate a 
skin cancer screening curriculum for internal medicine and family medicine interns, 
physician assistants, and nurse practitioners at Boston Medical Center. This study has two 
specific aims:  
1. Comparing pre- and post-course scores (average) of benign versus malignant 
lesions  
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2. Comparing pre- and post-course survey scores regarding the comfort level of 
primary care providers with the full body skin examination 
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REVIEW OF THE LITERATURE 
Overview 
 
Melanoma skin cancer 
Melanoma is the fifth leading cause of cancer in the United States of America2. Unlike 
most other cancers, the incidence and mortality of melanoma has been increasing over the 
past three decades2. There has been a three-fold increase in the incidence of melanoma 
since 19752. In 1975, the incidence of melanoma was 8.2 to 9.4 per 100,000 and this 
number rose to 24.2 to 35.4 in 20107. The incidence is estimated to increase 3.1 percent 
per year for males and 3.4 percent per year for females16. The overall lifetime risk for the 
development of melanoma in the United States is 1 in 482. The lifetime risk for men is 1 
in 52 and is 1 in 77 for women in the United States14. In 2016, it was estimated that 
76,400 people in the United States of America are diagnosed with melanoma and 10,100 
die of melanoma annually1. 
 Certain populations are at higher risk of developing melanoma than others. Many 
studies have explored the factors that increase one’s chance of developing melanoma. 
Older men are at increased risk of melanoma2. Since 1975, the risk of developing 
melanoma has doubled in men fifty to fifty-nine years old and quadrupled in men sixty to 
sixty-nine years old2. The risk has increased seven-fold in men older than eighty years 
old2. An immunocompromised state confers a three- to six-times increased risk of 
developing melanoma4. Those with genetic immunodeficiency syndromes are six times 
more likely of developing melanoma, while those with acquired immunodeficiency states 
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have a four times increased likelihood of developing melanoma4. Other melanoma risk 
factors include the presence of dysplastic nevi, personal or family history of melanoma, 
fair skin, and inability to tan3. Of those who develop melanoma, ninety-eight percent 
have at least one risk factor, seventy-five percent have two or more risk factors, thirty-
two percent have at least three risk factors, and five percent have four to five risk factors5. 
The more risk factors, the greater the likelihood of developing melanoma. Those with 
four to five risk factors have a 4.4 times increased likelihood of developing melanoma 
than those with one risk factor5.   
Atypical lesions are found grossly (figure 1) and the diagnosis of melanoma is 
confirmed by biopsy and histopathology. Biopsy is important for staging and prognosis 
of the melanoma (table 1). Survival is related to the thickness of the lesion at diagnosis. 
As tumor thickness increases, survival decreases9. Ten-year survival for patients with 
tumors less than or equal to 1.00 millimeter thick is ninety-two percent, and eighty 
percent for those with tumors 1.01 to 2.00 millimeters thick9. Patients with melanomas 
2.01 to 4.00 millimeters thick have a ten-year survival of sixty-three percent, and those 
with tumors greater than 4.00 millimeters thick have a fifty percent ten-year survival9. It 
is of great survival advantage to diagnose and treat thin, early-stage melanomas.  
	  
Figure 1: Melanoma17 
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Table 1: 2009 American Joint Committee on Cancer staging and prognosis of melanoma9. 
Stage Tumor Depth Nodal 
Involvement 
Metastases 5-Year 
Survival 
10-Year 
Survival 
In situ 0 mm (non-
invasive) 
None None   
IA ≤ 1.00 mm 
without 
ulceration 
None None 97% 93% 
IB ≤ 1.00 mm with 
mitoses or 
ulceration  
OR  
1.01-2.00mm 
without mitoses 
or ulceration 
None None   
IIA 1.01-2.00mm 
with ulceration 
OR 
2.01-4.00mm 
without 
ulceration 
None None 79-82%  
IIB 2.01-4.00mm 
with ulceration 
OR 
> 4.00mm 
without 
ulceration 
None None 68-71%  
IIC > 4.00mm with 
ulceration 
None None 53% 39% 
III Any thickness Yes None 40-78% 33-52% 
IV Any thickness Any nodal 
involvement 
Yes  One-year 
survival 
rates: 
33-62% 
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Non-melanoma skin cancer 
Non-melanoma skin cancer is a broad category encompassing basal cell carcinoma and 
squamous cell carcinoma. It is leading type of cancer in the United States of America and 
accounts for more than ninety-eight percent of all skin cancers1. Non-melanoma skin 
cancer rarely results in death or morbidity, accounting for less than 0.1 percent of patient 
deaths1. Doran et al. estimated the average years of healthy life lost to non-melanoma 
skin cancer – sixteen days in males and six days in females18. However, there is risk of 
metastasis and death as well as continued local growth and destruction; thus, these 
cancers must be treated8. Non-melanoma skin cancer risk factors are included in table 2.  
Table 2: Non-melanoma skin cancer risk factors8. 
Risk Factors for Non-Melanoma Skin Cancer 
UV exposure  
Number of sunburns  
Actinic keratosis  
Organ transplantation 
Fair complexion  
Arsenic exposure 
Family history of skin cancer 
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Basal cell carcinoma (figure 2) is the most common type of skin cancer8. It is 
primarily found on sun-exposed areas of the skin, for example the head and neck8. 
Lesions are slow-growing and may spread to surrounding tissues if untreated8. Although 
basal cell carcinoma rarely results in death, it accounts for a large amount of healthcare 
resources simply due to its high prevalence8.  
 
Figure 2: Basal cell carcinoma19 
Squamous cell carcinoma (figure 3) tends to occur in fair-skinned people with 
increased amounts of sun exposure8. Squamous cell carcinoma tends to arise from actinic 
keratoses, leukoplakia, or old scars8. Metastasis occurs in 0.5-16 percent of cases8.  
 
Figure 3: Squamous cell carcinoma20 
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Diagnosis 
Skin cancer is detected through a visual skin examination. Both the patient and the 
clinician can participate in the detection of skin cancer, although multiple studies have 
shown that clinicians find significantly thinner, earlier stage skin cancers than those 
detected by the patient or the patient’s significant other7.  
 There are multiple methods for performing the skin examination. One approach is 
to examine down the anterior portion of the body and then back up the posterior of the 
body7. Another possible method includes examination of the face, head, neck, and scalp 
followed by examination of the arms and hands, chest, abdomen, anterior legs and feet, 
and lastly posterior legs and feet7. It is recommended to pay particular attention to high-
risk melanoma sites, including the trunk for men and trunk and legs for women7. 
Photography can help clinicians document the evolution of lesions7. 
 The ABCDE mnemonic (table 3) is an important algorithm for detecting 
malignant skin lesions. It is the most commonly taught skin examination technique6. The 
Unites States Preventative Services Task Force reported that the ABCDE mnemonic has 
a sensitivity of 50-97% and a specificity of 96-99%8.  
Table 3: ABCDE mnemonic for detecting worrisome pigmented lesions8 
ABCDE Definition 
A Asymmetry 
B Border irregularity 
C non-uniform Color 
D Diameter > 6 mm 
E Evolving over time 
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 Dermoscopy can aid in a clinician’s assessment of benign versus malignant 
lesions. Clinicians can assess the pigmentation and structure of a lesion7. Melanoma tends 
to show more colors and structures that are asymmetrically distributed in the lesion 
compared to benign lesions7.  
Treatment 
Treatment for skin cancer depends on the stage at which the cancer is found. If skin 
cancer is found at an early stage, it can be cured by surgery alone10. Different surgical 
techniques for excision of non-melanoma skin cancers include Mohs micrographic 
surgery, curettage and electrodessication, and cryosurgery1. Early-stage melanoma is 
treated by wide local excision. Lymph node sampling may be performed depending on 
the lesion’s stage. 
 Metastatic melanoma requires a more aggressive treatment10. It requires a 
combination of chemotherapy, radiation therapy, targeted molecular therapy, and/or 
immunotherapy10. In 2011, new immunotherapy was added to the treatment of metastatic 
melanoma10. Ipilimumab augments the immune response against melanoma, which 
results in prolongation of life10. Other therapies that inhibit mutated versions of the 
BRAF protein include vemurafenib and dabrafenib, which also have been shown to 
significantly increase survival10. Even with treatment, medial survival is less than one 
year in patients with distant metastasis10.  
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Existing research 
Screening has helped reduce the mortality of the most common cancers2. Mammography 
for breast cancer, digital rectal exams and prostate screening antigen for prostate cancer, 
and colonoscopy for colorectal cancer have aided in early detection of some of the most 
common cancers in the United States2. There is a lack of randomized control trials to 
suggest that these screening methods decrease mortality; however, observationally, 
mortality has decreased for these cancers2.  
Patients at high-risk of developing melanoma represent at least half of the United 
States population21. Of the high-risk population, only twenty-four percent have had one 
total body skin examination in their lifetime, and only eleven percent have had a total 
body skin examination in the previous year21. When surveyed, eighty-one percent of 
dermatologists reported performing full body skin examinations on their patients, 
compared with only fifty-nine percent of family practitioners and fifty-six percent of 
internists22. It is controversial whether clinicians should be screening for melanoma. The 
American Cancer Society recommends routine screening for individuals twenty years old 
and older during their routine annual health exam21. The American College of Obstetrics 
and Gynecology recommends skin cancer screening only for high-risk individuals21.  
 The National Conference to Develop a National Skin Cancer Agenda identified 
melanoma as a disease that meets criteria for screening – its incidence is increasing, there 
is an asymptomatic period, there are available screening tools, and it is a disease that can 
be detected and treated early23. They recommend that primary care providers examine at 
least the exposed areas of skin for cancer. If an unusual lesion is identified, offices should 
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provide a protocol for follow up and biopsy23. Primary care providers are also 
recommended to counsel all patients regarding sun protection23.  
 The American Academy of Dermatology recommends annual total body skin 
examinations21. Screening of high-risk individuals, such as those with a family history of 
melanoma or those with clinically atypical nevi, may require more frequent screenings3.  
 The American Academy of Dermatology provides skin cancer screenings free of 
charge by volunteer dermatologists to numerous communities in the United States. This 
screening program started in 1985. Between 1985 and 1994, seven hundred forty-three 
thousand screenings have been performed and eight thousand people have been 
diagnosed with suspected melanoma as a result of this program24. There have been 
studies looking at the stage and thickness of melanomas found as a result of these 
screenings. These lesions were compared against the Surveillance, Epidemiology, and 
End Results data. The Surveillance, Epidemiology, and End Results data represents about 
ten percent of the United States population and it is considered a representative sample of 
the melanoma diagnoses in the United States24. Between 1989 and 1994, 98.9% of the 
lesions identified by the American Academy of Dermatology screening program were 
stages I and II24. Eighty-seven percent of the lesions were less than or equal to 1.50 mm 
while only 1.9% of the lesions were greater than or equal to 4.00 mm24. The median 
thickness of melanoma lesions was 0.30 mm24. There were fewer advanced-stage lesions 
identified in the American Academy of Dermatology screenings compared with the 
Surveillance, Epidemiology, and End Results data – 8.3% versus 16.9% respectively24. 
These results suggest that screening for melanoma results in an earlier stage at diagnosis, 
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which confers a survival advantage. This study also looked at the number of melanomas 
identified by screening. Melanoma was identified in 129 people per 100,000 screened24. 
When looking at the high-risk population of men fifty years old and older, the diagnostic 
yield for melanoma increased to 240 per 100,00024. This suggests that identifying and 
screening high-risk populations will decrease the number needed to screen and possibly 
make screening more cost-effective.  
 In 2009 and again in 2016, the United States Preventative Services Task Force 
(USPSTF) stated that there was insufficient evidence to recommend routine melanoma 
screening by clinicians. In 2009, the USPSTF claimed that there were two gaps in the 
literature: limited evidence that screening for melanoma improved survival and 
insufficient evidence that primary care providers are adequate at performing a screening 
examination for melanoma8. The USPSTF cites that no randomized control trials have 
been conducted to compare the morbidity and mortality of melanoma patients who were 
screened versus unscreened8. This is understandable given the questionable ethics of such 
a study.  
In 2016, the USPSTF again investigated the current evidence regarding screening 
for melanoma. Again, the USPSTF stated that there was insufficient evidence to 
recommend screening for melanoma1. This time, however, the USPSTF cited the inability 
to conclude that the benefits of screening outweighed the harms1. The only study the 
USPSTF found demonstrating the benefits of skin cancer screening in reducing mortality 
due to melanoma was the SCREEN program out of Germany1. Evidence regarding harms 
of screening is also lacking1. Possible adverse effects of visual screening for melanoma 
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included overdiagnosis, overtreatment, and cosmetic or functional adverse events1. The 
USPSTF does state that clinicians need to understand the research and its limitations, and 
the recommendation is not meant to be a one-size-fits all. Clinicians should make 
decisions based on the patient and clinical scenario1.  
In 2003-2004, a skin cancer screening project was conducted in Northern 
Germany, called the SCREEN (Skin Cancer Research to Provide Evidence for the 
Effectiveness of Screening in Northern Germany) project. Participating providers, both 
dermatologists and primary care physicians, underwent an eight-hour training course 
covering the epidemiology, etiology, and diagnosis of melanoma as well as instruction on 
performing the full body skin examination25. After one year, incidence rates of melanoma 
increased by about thirty percent in the screened population while the overall incidence in 
Germany itself remained stable25. Of the melanomas detected in the SCREEN project, 
more than ninety percent of the invasive lesions were less than one millimeter thick, 
indicating that screening was finding more cancers at a lower stage25. Malignant 
melanoma mortality rates decreased by about fifty percent over a ten year period in the 
screened region of Germany while the rates remained constant in Germany as a whole25. 
After the promising results from the SCREEN program, Germany instituted a 
national skin cancer screening program in which all adults aged thirty-five and older were 
screened for melanoma every two years25. The incidence of melanoma increased by 
twenty-eight percent in Germany25, which was to be expected as increased surveillance 
would lead to a greater number of new diagnoses. Disappointingly, the mortality rate in 
Germany has not decreased as was expected following the SCREEN pilot study25. There 
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are some factors that might contribute to the lack of mortality benefit seen in the 
nationwide screening program, including less intensive skin cancer screenings than those 
used in the SCREEN program and the need of a longer time to see results in such a large 
population25. Interestingly, the incidence and mortality rates in the region of Northern 
Germany where the SCREEN project took place have returned to the pre-SCREEN 
project levels25. It is possible that the mortality benefit seen in the pilot study was simply 
the result of normal variation. 
There is an interesting phenomenon called melanoma of unknown primary. 
Between one and four percent of melanoma patients are identified with metastatic disease 
without ever being diagnosed with a primary cutaneous melanoma28. The underlying 
etiology is unknown, but one possible explanation is that providers are missing the 
primary lesion on physical exam28. Another interesting observation about melanoma of 
unknown primary is that these patients seem to have a survival advantage over other 
patients with metastatic melanoma with a known primary lesion – sixteen months versus 
eleven months, respectively (p < 0.001)28. Lee et al. hypothesized that the immune 
systems in those with melanoma of unknown primary may be superior to those with 
melanoma of known primary28. If the immune system rid the body of the primary lesion, 
the immune system may also be strong enough to partially fight the metastatic lesions. 
Despite the fact that these patients have a survival advantage, they still have stage IV 
disease and survive only a median of sixteen months28. Imagine the survival advantage 
for those patients who had a cutaneous primary lesion, if it had been instead detected at 
an early stage.   
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There is a fair amount of evidence on the ability of primary care providers to 
diagnose melanoma. Studies have shown that physicians find thinner melanomas than 
those picked up by patients themselves or their significant others. Geller et al. compared 
the thickness and stage of melanomas found by physicians, patients, and significant 
others26. Sixty-nine percent of lesions found by physicians were less than or equal to one 
millimeter thick, significantly thinner than those found by significant others and patient-
detected (fifty percent [p = 0.04] and thirty-three percent [p < 0.001], respectively)26. Ten 
percent of physician-found lesions were late-stage, compared with twenty-eight percent 
of significant other-detected lesions (p = 0.02) and thirty-five percent of self-detected 
lesions (p = 0.001)26. The most important prognostic factor in melanoma is the depth of 
the lesion. Five-year survival of melanoma in situ is ninety-nine percent compared with 
forty-five to seventy-nine percent in lesions 1.01-2.0 millimeters27. Therefore, if 
physicians detect thinner melanomas than those found by a patient’s significant other or 
by the patient themself, we would expect increased physician screening to subsequently 
increase five-year survival from melanoma.  
Multiple studies have examined the difference between lesions detected by 
dermatologists versus primary care physicians. Pennie et al. explored thickness and stage 
at diagnosis as well as survival and mortality in dermatologists versus non-
dermatologists14. Dermatologists detected significantly thinner melanomas compared 
with non-dermatologists (0.86 millimeters thick versus 1.00 millimeters thick, 
respectively [p < 0.05])14. Dermatologists also detected significantly more melanomas at 
stage 0 or I compared with non-dermatologists who found more melanomas at stages III 
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and IV (p < 0.01)14. Survival was superior in the dermatology group than in the non-
dermatology group at six months, two years, and five years (p < 0.05)14. A lower cancer-
related mortality rate was associated with dermatologists compared with non-
dermatologists14.  
The 2009 USPSTF recommendation stated that there is insufficient evidence 
regarding the accuracy of primary care providers in the diagnosis of melanoma8. There is, 
in fact, a large amount of evidence regarding the length of dermatology training in both 
medical school and residency programs, and the result is dismal. Most surveys report a 
small amount of time spent on dermatology in medical school and most residents feel 
uncomfortable performing the full body skin examination.  
Moore et al. examined the amount of dermatology exposure in fourth year 
medical students in seven medical schools in the United States12. Twenty-three percent of 
medical students had never seen a full body skin examination performed, twenty-six 
percent had never received training in the full body skin examination, and forty-three 
percent had never performed a full body skin examination12. Sixty-nine percent of fourth 
year medical students agreed that there was too little emphasis on the full body skin 
examination during their medical training12. Twenty-eight percent of students reported 
that they were skilled in the full body skin examination, a number that decreases to 
nineteen percent if the student had not completed a dermatology elective rotation12. 
Increased skill level in the full body skin examination was associated with observing, 
training, and practicing the examination12. A staggering seventy-two percent of 
	  19 
graduating medical students self-report that they are not skilled in performing the full 
body skin examination12.  
  Buster et al. reported that less than one percent of the undergraduate medical 
education is devoted to dermatology (about sixteen to twenty-two hours)29. Less than 
forty percent of primary care residents report that their medical education adequately 
prepared them to diagnose and treat common skin conditions29. Hansra et al. reported that 
twenty-eight percent of residents felt adequately prepared to treat common dermatologic 
conditions15. Participation in a dermatology elective rotation during medical school 
increased the percentage of residents who felt adequately prepared to diagnose and treat 
common dermatologic conditions15.  
 Wise et al. surveyed four residency programs to determine the skill level of the 
residents in performing the full body skin examination11. Seventy-five percent of 
residents had never been trained in the full body skin examination, fifty-five percent had 
never observed a full body skin examination, and fifty-seven percent had never practiced 
the full body skin examination11. Fifteen percent of primary care residents reported that 
they were skilled in the full body skin examination11. 
 If the majority of residents are not confident in their full body skin examination 
and think their medical training inadequately prepared them to diagnose common 
dermatological skin conditions, how many primary care providers actually perform a full 
body skin examination? Kirsner et al. found that thirty-one percent of primary care 
providers perform full body skin examinations on every patients13. Of those who do not 
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perform full body skin examinations on all their patients, thirty-one percent report 
examining high-risk patients13.  
Oliveria et al. examined the barriers to performing the full body skin examination 
in both primary care physicians as well as dermatologists22. Primary care physicians 
reported that their biggest barriers to performing the full body skin examination were 
time constraints and competing comorbidities22. Of note, dermatologists took 
significantly more time to perform a full body skin examination compared with family 
practitioners and internists22. Dermatologists reported that skill in the full body skin 
examination and medical training were facilitating factors to their willingness to 
performing a full body skin examination22. All specialties cited patients having one or 
more skin cancer risk factors as being a facilitating factor in performing the full body 
skin exam22. 
Primary care physicians report time as a major barrier to performing full body 
skin examinations. How much time does it take? There is controversy in the literature 
regarding this subject. Hantirah et al. reported a mean time of just over six minutes to 
complete a full body skin examination30. A longer examination was associated with older 
age of patient (p = 0.024) and the use of tools (p < 0.0001). In this study, the full body 
skin examination included a general visual examination as well as any necessary special 
examinations but did not include history taking or counseling30. Zalaudek et al. recorded 
a median duration of seventy seconds to perform the full body skin examination31. 
Including dermoscopy in the examination was associated with a significantly increased 
examination time of one hundred forty-two seconds (p < 0.001)31. In fact, an increased 
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number of nevi on the patient was associated with a decreased time to complete a full 
body skin examination, which was attributed to pattern recognition31. Of note, this study 
was performed by dermatologists with an interest in skin cancer; also, the scalp, genitals, 
mucus membranes, and conjunctiva were excluded from the full body skin examination31.  
Do physicians need to perform a full body skin examination on all patients? In the 
free screenings performed by the American Academy of Dermatology, greater than thirty 
percent of the lesions were located on the posterior of the patient24. Other sites included 
the upper limb, lower limb, back, head and neck, chest, and abdomen24. The majority of 
melanomas were found on the trunk in men and on the posterior legs in women7.  
However, recently melanoma of the trunk has been increasing in incidence in women 
younger than forty years old32. Additionally, patients who receive a full body skin 
examination are more likely to be diagnosed with suspected melanoma than those who 
receive a partial examination (OR = 1.4, 95% CI 1.3-1.6)5. Clearly, there is an advantage 
to examining all aspects of the skin surface.   
 There is not good quality evidence on a recommended interval of time between 
screenings. The nationwide German screening project screened individuals every two 
years25. Watts et al. conducted a systematic review and reported low-level evidence that 
individuals with atypical nevi should have regular full body skin examinations every six 
to twelve months and consensus-based evidence that individuals at high risk should be 
monitored twice per year for life3. 
Most cost-effectiveness analyses compare one-time screens to screening every 
two years. Losina et al. reported that it was cost-effective to screen the general United 
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States population fifty years old and older once and every two years for individuals with 
a history of melanoma in first-degree relatives33. Freedberg et al. reported that screenings 
would be cost-effective if greater than or equal to ninety-four percent of lesions found on 
screenings were localized34. In this study, localized was defined as melanoma in situ or 
melanoma of any thickness as long as there was no spread to lymph nodes or distant 
metastases34. Goldsmith et al. reported that ninety-eight percent of lesions found by the 
American Academy of Dermatology free screening program were stages I and II23. These 
data altogether confirm that screening is cost-effective, especially when screening those 
at high-risk for developing melanoma.  
Tsao et al. examined the costs of treating different stages of melanoma35. Stages I 
and II cost about five percent of the total annual cost of melanoma in the United States 
while stage III comsumes thirty-four percent of the cost and stage IV consumes fifty-five 
percent of the total annual cost35. Eighty percent of melanomas account for ten percent of 
the total annual cost of treating melanoma and twenty percent of patients consume ninety 
percent of the total annual cost35. If physicians find thinner melanomas than those found 
by patients, then screening by physicians should decrease the number of stage III and IV 
melanomas and thus decrease the annual cost to treat melanoma.  
 Why primary care physicians and not dermatologists? There is a shortage of 
dermatologists in the United States relative to the demand15. The average American visits 
his or her primary care provider twice per year2. Men older than fifty years old – a high-
risk group for the development of melanoma – average three to four primary care visits 
per year2. Melanoma risk is associated with not having a regular dermatologist (OR = 1.4, 
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95% CI 1.3-1.5)5. Thus, it makes sense to have the primary care providers function as the 
triage providers for dermatologists – referring the patients who need to be further 
evaluated. 
Some countries have employed the use of teledermatologists to account for the 
shortage of dermatologists. Aldridge et al. found that one third of melanomas would be 
missed if a full body skin examination was not performed36. Simply sending pictures of 
index lesions to a teledermatologist may result in many of these lesions being missed36.  
 Skin disorders are the number one reason why patients visit their doctor37. St. 
Sauver et al. found that skin conditions are the most common presenting complaint of 
patients less than sixty-five years old37. For the patients sixty-five years old and older, 
skin disorders represent the third most common presenting complaint37. If a patient is 
presenting with a skin condition, it is quite reasonable that a physician would check the 
patient’s skin, so why not take the opportunity to examine the patient head-to-toe.  
 McCleskey et al. reported on the efficacy of online modules in the education of 
residents and physician assistant students38. Higher pre-test scores were associated with 
having taken a prior dermatology elective (p = 0.003)38. All scores significantly improved 
after completion of the curriculum (p < 0.01)38. There was no difference in scores 
between residents and physician assistant students (pretest p = 0.09, post-test p = 0.40)38. 
Participants also took the same post-test months later to assess long-term knowledge 
retention38. The scores were slightly lower than those of the immediate post-test (p = 
0.012), but the average of the long-term follow up post-test was higher than that of the 
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pre-test indicating that the dermatology knowledge was retained38. Interestingly, post-test 
scores were not associated with a prior dermatology rotation (p = 0.38)38.  
 Wise et al. surveyed residents regarding their comfort in the full body skin 
examination and their input on how to adequately incorporate teaching the full body skin 
examination into residency programs11. Thirty-seven percent of residents preferred core 
curriculum classes while only seventeen preferred departmental lessons and eight percent 
thought grand rounds sessions would be ideal11.  
 An ongoing study through the University of Pittsburgh Medical Center is 
exploring the effect of training primary care residents in skin cancer screening39. The 
primary care residents are participating in a one and a half hour online training module. 
Ferris et al. have found that primary care residents who had completed the online training 
module were significantly more likely to provide annual skin examinations to their 
patients than those who had not completed the training (p < 0.001)39. Primary care 
residents who had completed the online training were significantly more likely to 
diagnose melanomas than their colleagues who had not completed the training (p < 
0.001)39. Melanomas found by the primary care residents who had completed the training 
were significantly thinner (p = 0.023) and more likely to be in situ (but not statistically 
significant, p = 0.168) compared with those who had not completed the online training 
module39. 	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METHODS 
Study design 
This study will be a curriculum seeking to teach medical residents, physician assistants 
(PAs), and nurse practitioners (NPs) the full body skin examination as well as 
identification of benign versus malignant skin lesions.  
 
Study population and sampling 
Subjects will be recruited from post-graduate year 1 internal medicine and family 
medicine residents as well as PAs/NPs at Boston Medical Center. There are fifty-six 
internal medicine, twelve family medicine interns, and about twenty-four primary care 
PAs/NPs at Boston Medical Center. The population in this study is representative of the 
primary care and family medicine interns as well as PAs/NPs in the United States.  
 	  
Intervention 
Participants will participate in three one-hour long sessions during the noon conference 
allotted for Internal Medicine and Family Medicine interns as well as PAs/NPs. Learning 
objectives will include:  
1. Discuss the importance of performing the body skin examination 
2. Describe the epidemiology of benign versus malignant skin conditions 
3. Discuss the risk factors for the development of skin cancer  
4. Classify benign skin lesions  
5. Classify malignant skin lesions  
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6. Prepare patient education and counseling on preventative practices  
7. Evaluate when referrals to a specialist are warranted  
8. Evaluate skin lesions based on the ABCDE mnemonic  
A pre-test and pre-course survey will be emailed prior to the course that must be 
completed before the first session. The pre-test will contain ten images and participants 
will be asked to identify the skin lesion images as “benign” or “malignant.” The survey 
will contain questions regarding the participant’s clinical practice.  
Participants will be asked to perform a full body examination on standardized 
patients during the first and third sessions. A different standardized patient will be used 
for each session so the participants can become comfortable with different skin types. 
Standardized patients will have a lesion for the provider to find – a benign nevus, actinic 
keratosis, seborrheic keratosis, et cetera. If the standardized patient does not have a skin 
lesion, a lesion will be applied to the foot of the standardized patient using makeup. The 
standardized patients will provide qualitative oral feedback to the participants. Feedback 
will include the comfort level of the provider as observed by the standardized patient, 
identification of skin lesions, and length of time taken to perform the full body skin 
examination. This will be for the purpose of practicing the full body examination and will 
not be included in the data analysis  
 The second session will consist of a lecture that will contain both elements of the 
full body examination as well as identification of benign versus malignant skin lesions.  
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Study variables and measures 
The pre-test, immediate post-test, and six-month post-test will be an online module where 
the participant will be asked to identify benign versus malignant skin lesions. Links will 
be emailed to participants one week prior to the course, immediately after the course, and 
then six months after completion of the course. There will be a total of ten questions and 
the participant will receive his/her score at the end of the test. The questions will be 
randomized from a bank of fifty images. The test will include 4-6 malignant lesions, 
including early-stage and late-stage melanomas, squamous cell carcinomas, and basal cell 
carcinomas. The 4-6 benign lesions will include lesions such as actinic keratosis, lichen 
planus, seborrheic dermatitis, seborrheic keratosis, and dermatofibroma. No retries of the 
test will be allowed. Pre-test scores will be compared with both the immediate post-test 
as well as the six-month post-test to assess the immediate effectiveness of the course as 
well as the long-term retention of the material. 
 Surveys will be included in the emailed link at the end of all of the tests. The 
survey prior to the course and the six-month survey will contain the same questions to 
assess the change in clinical practice (table 4). Means and standard deviations will be 
calculated. Clinical significance will be defined as an increase of 1 point from the pre-
course Likert score to the post-course Likert Score. The immediate post-course survey 
will be directed at assessing the effectiveness of the course itself (table 5).  
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Table 4: Pre- and six-month post-survey 
Measure 1 point 2 points 3 points 4 points 5 points 
How do you 
decide on 
whom you 
perform full 
body skin 
examinations? 
I never 
perform full 
body skin 
examinations 
Time 
permitting 
If the patient 
has a specific 
concern 
All high-
risk patients 
I perform full 
body skin 
examinations 
on all of my 
patients  
How 
comfortable 
do you feel in 
performing a 
full body skin 
examination? 
Very 
uncomfortable  
Somewhat 
uncomfortable  
Neither 
comfortable 
nor 
uncomfortable 
Somewhat 
comfortable 
Very 
comfortable  
In the past 6 
months, how 
many referrals 
have you 
made to 
dermatology? 
0 1-3 4-7 8-10 > 10 
In the past 6 
months, how 
many skin 
lesions have 
you 
documented? 
0 1-3 4-7 8-10 > 10 
In the past 6 
months, how 
many skin 
cancers have 
you 
identified? 
0 1-3 4-7 8-10 > 10  
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Table 5: Immediate post-course survey 
Measure 1 point 2 points 3 points 
Did this 
course 
convey the 
importance 
of the skin 
examination? 
Ineffective Neither 
effective nor 
ineffective  
Effective 
How 
effective was 
this course at 
improving 
your skills in 
performing 
the full body 
skin 
examination? 
Ineffective Neither 
effective nor 
ineffective 
Effective 
To what 
degree did 
your 
confidence 
improve in 
your ability 
to identify 
benign 
versus 
malignant 
skin lesions? 
Ineffective Neither 
ineffective 
nor effective 
Effective  
Will this 
course 
change your 
practice 
No Maybe Yes  
Comments 
and 
suggestions 
for 
improvement  
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Recruitment 
All Boston Medical Center post-graduate year 1 Internal Medicine and Family Medicine 
residents as well as Hospitalist PAs/NPs will be invited to participate in this curriculum. 
All participants will receive the same instruction. Attendance will be voluntary, but 
strongly encouraged. Standardized patient encounters will be offered on several days to 
maximize providers’ ability to participate in this intervention. The lecture-based didactic 
portion, session two, will be given four separate times at the noon conference in the 
Ambulatory Medicine block to capture different subsets of interns as they change 
rotations.   
 
Data collection 
Data will be collected using an emailed link to an online module. Participants will be 
presented a skin lesion and asked to identify said lesion as “benign” or “malignant.” At 
the end of the ten-question test will be a survey. Pre-course and six-month post-course 
surveys will be the same, aimed at assessing how the course changed clinical practice 
(table 4). The immediate post-course survey will be aimed at assessing the effectiveness 
of the course and improving the course in the future (table 5). Participants will receive 
immediate feedback on the correct answers to the skin lesion questions after submitting 
the surveys. All questions must be answered and once an answer is submitted, it may not 
be changed.  
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Data analysis 
Scores from the pre-test will be compared with the immediate post-test as well as six-
month post-test scores. Average and standard deviation will be calculated for all of the 
tests. The scores will be analyzed using a paired T-test to assess participants’ ability to 
identify benign versus malignant lesions both immediately after the course and long-term 
retention of the material. 
 Pre-course and six-month post-course surveys will be analyzed to assess how the 
course changed clinical practice using a paired T-test for the Likert scale. Overall Likert 
score with mean and standard deviation will be calculated. Mean and standard deviations 
will be calculated for individual components of the Likert scale: the determining factors 
for performing a full body skin examination (question 1), the comfort in performing a full 
body skin examination (question 2), and the number of referrals/suspicious lesions 
documented/skin cancers identified (questions 3, 4, 5). An increase of 1 from the pre-
course survey to the post-course survey in any section of the Likert scale will be 
considered a clinically significant difference. 
 It is expected that the pre-course quiz average will be 60% or lower and the post-
course quiz average will be 85% or higher. With a sample size of 68 interns and 24 
PAs/NPs, the calculated power is 0.97. 
Immediate post-course surveys will be reviewed to assess the success of the 
course in meeting the learning objectives, and to help improve the course in the future.  
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Timeline and resources 
Summer 2017  
IRB submission and approval 
Development of curriculum for lecture  
Book standardized patients  
Fall 2017 
Development of pre-course and post-course tests and surveys   
Training of standardized patients  
Spring 2018 
Dispersal of email links with pre-course test and survey 
Twelve one-hour sessions at noon conference  
Dispersal of email links with immediate post-course test and survey 
Fall 2018 
Dispersal of email links with six-month post-course test and survey 
Data analysis  
Manuscript preparation  
Winter 2018 
Submit manuscript for peer review  
 
Institutional Review Board 
This study will be submitted to the Boston Medical Center Institutional Review Board for 
exemption for educational studies under 45 CFR 46 101 (b) criteria.  
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CONCLUSION 
Discussion 
This study is aimed at improving skin cancer screening in primary care. There are some 
limitations of this study. First of all, there is a limited amount of family medicine and 
internal medicine interns and PAs/NPs at Boston Medical Center, making the sample size 
small. Another potential limitation is the responses to the emailed surveys. Participation 
is completely voluntary and with the busy schedules of clinicians, surveys may not be 
returned, further limiting the amount of data.  
 One obstacle for this study is the United States Preventative Services Task Force 
report that there is insufficient evidence for primary care providers to perform the full 
skin examinations1. This could be problematic both in the approval process for the study 
as well as clinician participation. From the proposal aspect, why should there be a study 
about whether teaching the full skin examination improves both comfort with the 
examination and detection of suspicious skin lesions if primary care providers will not 
get reimbursed for performing the examination? From the clinician standpoint, why 
should time be spent learning something that is not even recommended in clinical 
practice? One of the cited reasons the United States Preventative Services Task Force 
does not recommend the full skin examination is due to insufficient evidence that primary 
care physicians can accurately perform a skin examination8. The hope is that teaching 
clinicians the full skin examination and identification of benign versus malignant skin 
lesions will provide the evidence that the United States Preventative Services Task Forces 
argues is lacking.   
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 Why not go to the source and teach students? The aim of this study is to teach 
clinicians who are practicing in primary care. Medical students and PA/NP students can 
enter any field and by the time they start practicing, they still may not have practiced a 
full body skin examination on a patient by the time they enter residency or clinical 
practice. Residents and PAs/NPs can begin practicing full body skin examinations 
immediately after the course and integrate the examination into their clinical practice. 
The practicing primary care providers can then teach students who are rotating on an 
internal medicine or family medicine rotation. Therefore, the purpose of this study is not 
only to teach the examination, but also to have the practicing clinicians integrate skin 
cancer screening into their exam and teach future clinicians.  
 Although there is a current study exploring the benefit of teaching residents skin 
cancer screening, this is the first study including both practicing residents and practicing 
PAs/NPs, making this study unique.  
 
Summary 
Melanoma is a leading cause of cancer in the United States and its incidence is 
increasing2. Prognosis for melanoma is related to stage and thinness of the lesion at 
diagnosis9. Although clinicians find thinner, earlier stage melanomas than patients 
themselves or patients’ significant others7, medical schools only dedicate one percent of 
undergraduate medical school education to dermatology29. The majority of primary care 
residents have not been trained in the full body skin examination for melanoma 
screening11 and the minority are comfortable with diagnosing common dermatologic 
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complaints15. There is a shortage of dermatologists relative to the demand15; thus, it is the 
responsibility of the primary care provider to triage skin lesions and refer suspicious 
lesion to the dermatologist.  
 This project is aimed at creating a curriculum that will teach residents and 
PAs/NPs the full body skin examination as well as identification of benign versus 
malignant skin lesions. The results of this study will attempt to increase the number of 
clinicians who are not only comfortable with performing the full body skin examination, 
but also have an understanding of benign versus malignant lesions should they find a 
lesion in clinical practice.  
 
Clinical and/or public health significance 
In both the outpatient and inpatient realms, full body skin examinations are important; 
however, according to the United States Preventative Services Task Force, primary care 
providers do not perform adequate full body skin examinations1. It is the hope that this 
study will show that primary care providers are capable of performing the full body skin 
examination as well as identifying malignant lesions. Another goal is that these clinicians 
will take with them the confidence to perform full body skin examinations and the tools 
to identify potentially cancerous lesions. It is the ultimate goal that the clinicians who 
participate in this study will modify their practice to include the full body skin 
examination on their patients. 
	  36 
LIST OF JOURNAL ABBREVIATIONS 
Acta Derm Venereol  Acta Dermato Venereologica  
Ann Med. Annals of Medicine  
Arch Dermatol Archives of Dermatology 
Br J Dermatol British Journal of Dermatology  
Cancer Epidemiol Biomarkers Prev Cancer Epidemiology Biomarkers & Prevention  
Clin Dermatol Clinics in Dermatology  
Curr Oncol Current Oncology  
Dermatol Clin Dermatologic Clinics  
Dtsch Ärztebl Int Deutsches Ärzteblatt International  
J Am Acad Dermatol Journal of the American Academy of Dermatology  
JAMA The Journal of the American Medical Association 
J Clin Aesthetic Dermatol The Journal of Clinical and Aesthetic Dermatology  
J Clin Oncol Journal of Clinical Oncology  
J Gen Intern Med  Journal of General Internal Medicine  
Mayo Clin Proc Mayo Clinic Proceedings  
Prev Med  Preventative Medicine  
  
	  37 
REFERENCES 
1.  Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for Skin Cancer: US 
Preventive Services Task Force Recommendation Statement. JAMA. 
2016;316(4):429-435. doi:10.1001/jama.2016.8465. 
2.  Shellenberger R, Nabhan M, Kakaraparthi S. Melanoma screening: A plan for 
improving early detection. Ann Med. 2016;48(3):142-148. 
doi:10.3109/07853890.2016.1145795. 
3.  Watts C g., Dieng M, Morton R l., Mann G j., Menzies S w., Cust A e. Clinical 
practice guidelines for identification, screening and follow-up of individuals at high 
risk of primary cutaneous melanoma: a systematic review. Br J Dermatol. 
2015;172(1):33-47. doi:10.1111/bjd.13403. 
4.  Jen M, Murphy M, Grant-Kels JM. Childhood melanoma. Clin Dermatol. 
2009;27(6):529-536. doi:10.1016/j.clindermatol.2008.09.011. 
5.  Goldberg MS, Doucette JT, Lim HW, Spencer J, Carucci JA, Rigel DS. Risk factors 
for presumptive melanoma in skin cancer screening: American Academy of 
Dermatology National Melanoma/Skin Cancer Screening Program experience 2001-
2005. J Am Acad Dermatol. 2007;57(1):60-66. doi:10.1016/j.jaad.2007.02.010. 
6.  Goulart JM, Quigley EA, Dusza S, et al. Skin Cancer Education for Primary Care 
Physicians: A Systematic Review of Published Evaluated Interventions. J Gen 
Intern Med. 2011;26(9):1027-1035. doi:10.1007/s11606-011-1692-y. 
7.  Kaufman HL, Mehnert JM, eds. Melanoma. Vol 167. Cham: Springer International 
Publishing; 2016. http://link.springer.com/10.1007/978-3-319-22539-5. Accessed 
June 5, 2016. 
8.  Wolff T, Tai E, Miller T. Screening for Skin Cancer: An Update of the Evidence for 
the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare 
Research and Quality (US); 2009. http://www.ncbi.nlm.nih.gov/books/NBK34051/. 
Accessed June 9, 2016. 
9.  Balch CM, Gershenwald JE, Soong S, et al. Final Version of 2009 AJCC Melanoma 
Staging and Classification. J Clin Oncol. 2009;27(36):6199-6206. 
doi:10.1200/JCO.2009.23.4799. 
10.  McCarron CE, Ernst S, Cao JQ, Zaric GS. Population-based estimates of survival 
and cost for metastatic melanoma. Curr Oncol. 2015;22(5):326. 
doi:10.3747/co.22.2557. 
	  38 
11.  Wise E, Singh D, Moore M, et al. Rates of skin cancer screening and prevention 
counseling by us medical residents. Arch Dermatol. 2009;145(10):1131-1136. 
doi:10.1001/archdermatol.2009.242. 
12.  Moore MM, Geller AC, Zhang Z, et al. Skin cancer examination teaching in US 
medical education. Arch Dermatol. 2006;142(4):439-444. 
doi:10.1001/archderm.142.4.439. 
13.  Kirsner RS, Muhkerjee S, Federman DG. Skin cancer screening in primary care: 
Prevalence and barriers. J Am Acad Dermatol. 1999;41(4):564-566. 
doi:10.1016/S0190-9622(99)80053-X. 
14.  Pennie ML, Soon SL, Risser JB, Veledar E, Culler SD, Chen SC. Melanoma 
outcomes for medicare patients: Association of stage and survival with detection by 
a dermatologist vs a nondermatologist. Arch Dermatol. 2007;143(4):488-494. 
doi:10.1001/archderm.143.4.488. 
15.  Hansra NK, O’Sullivan P, Chen CL, Berger TG. Medical school dermatology 
curriculum: Are we adequately preparing primary care physicians? J Am Acad 
Dermatol. 2009;61(1):23-29.e1. doi:10.1016/j.jaad.2008.11.912. 
16.  Miller KA, Langholz BM, Zadnick J, et al. Prevalence and Predictors of Recent 
Skin Examination in a Population-Based Twin Cohort. Cancer Epidemiol 
Biomarkers Prev. 2015;24(8):1190-1198. doi:10.1158/1055-9965.EPI-14-1389. 
17.  Unknown. English: This Slide Shows a Melanoma on a Patient’s Skin.; 1985. 
https://commons.wikimedia.org/wiki/File:Melanoma.jpg. Accessed December 21, 
2016. 
18.  Doran CM, Ling R, Byrnes J, et al. Estimating the economic costs of skin cancer in 
New South Wales, Australia. BMC Public Health. 2015;15(1). doi:10.1186/s12889-
015-2267-3. 
19.  Germany KDP Gummersbach. Nodular Basal Cell Carcinoma in 75-Year-Old 
Man.; 2012. https://commons.wikimedia.org/wiki/File:Basalioma_02.jpg. Accessed 
December 21, 2016. 
20.  BruceBlaus. English: Squamous Cell Carcinoma. See a Full Animation of This 
Medical Topic.; 2015. 
https://commons.wikimedia.org/wiki/File:Squamous_Cell_Carcinoma.png. 
Accessed March 16, 2017. 
21.  Lakhani NA, Saraiya M, Thompson TD, King SC, Guy GP. Total body skin 
examination for skin cancer screening among U.S. adults from 2000 to 2010. Prev 
Med. 2014;61:75-80. doi:10.1016/j.ypmed.2014.01.003. 
	  39 
22.  Oliveria SA, Heneghan MK, Cushman LF, Ughetta EA, Halpern AC. Skin cancer 
screening by dermatologists, family practitioners, and internists: Barriers and 
facilitating factors. Arch Dermatol. 2011;147(1):39-44. 
doi:10.1001/archdermatol.2010.414. 
23.  Goldsmith LA, Koh HK, Bewerse BA, et al. Full proceedings from the National 
Conference to Develop a National Skin Cancer Agenda. J Am Acad Dermatol. 
1996;35(5):748-756. doi:10.1016/S0190-9622(96)90731-8. 
24.  Koh HK, Norton LA, Geller AC, et al. Evaluation of the American Academy of 
Dermatology’s National Skin Cancer Early Detection and Screening Program. J Am 
Acad Dermatol. 1996;34(6):971-978. doi:10.1016/S0190-9622(96)90274-1. 
25.  Katalinic A, Eisemann N, Waldmann A. Skin Cancer Screening in Germany: 
Documenting Melanoma Incidence and Mortality From 2008 to 2013. Dtsch Ärztebl 
Int. 2015;112(38):629. doi:10.3238/arztebl.2015.0629. 
26.  Geller AC, Johnson TM, Miller DR, Brooks KR, Layton CJ, Swetter SM. Factors 
associated with physician discovery of early melanoma in middle-aged and older 
men. Arch Dermatol. 2009;145(4):409-414. doi:10.1001/archdermatol.2009.8. 
27.  Chiaravalloti AJ, Laduca JR. Melanoma Screening by Means of Complete Skin 
Exams for All Patients in a Dermatology Practice Reduces the Thickness of Primary 
Melanomas at Diagnosis. J Clin Aesthetic Dermatol. 2014;7(8):18. 
28.  Lee CC, Faries MB, Wanek LA, Morton DL. Improved Survival for Stage IV 
Melanoma From an Unknown Primary Site. J Clin Oncol. 2009;27(21):3489-3495. 
doi:10.1200/JCO.2008.18.9845. 
29.  Buster KJ, Stevens EI, Elmets CA. Dermatologic Health Disparities. Dermatol Clin. 
2012;30(1):53-59. doi:10.1016/j.det.2011.08.002. 
30.  Hantirah SA, Yentzer BA, Karve SJ, McCallister M, Yarbrough CM, Feldman SR. 
Estimating the time required for a complete skin examination. J Am Acad Dermatol. 
2010;62(5):886-888. doi:10.1016/j.jaad.2009.03.024. 
31.  Zalaudek I, Kittler H, Marghoob AA, et al. Time required for a complete skin 
examination with and without dermoscopy: A prospective, randomized multicenter 
study. Arch Dermatol. 2008;144(4):509-513. doi:10.1001/archderm.144.4.509. 
32.  Bradford PT, Anderson WF, Purdue MP, Goldstein AM, Tucker MA. Rising 
Melanoma Incidence Rates of the Trunk among Younger Women in the United 
States. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2401-2406. 
doi:10.1158/1055-9965.EPI-10-0503. 
	  40 
33.  Losina E, Walensky RP, Geller A, et al. Visual screening for malignant melanoma: 
A cost-effectiveness analysis. Arch Dermatol. 2007;143(1):21-28. 
doi:10.1001/archderm.143.1.21. 
34.  Freedberg KA, Geller AC, Miller DR, Lew RA, Koh HK. Screening for malignant 
melanoma: A cost-effectiveness analysis. J Am Acad Dermatol. 1999;41(5):738-
745. doi:10.1016/S0190-9622(99)70010-1. 
35.  Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating 
cutaneous melanoma. J Am Acad Dermatol. 1998;38(5):669-680. 
doi:10.1016/S0190-9622(98)70195-1. 
36.  Aldridge R, Naysmith L, Ooi E, Murray C, Rees J. The Importance of a Full 
Clinical Examination: Assessment of Index Lesions Referred to a Skin Cancer 
Clinic Without a Total Body Skin Examination Would Miss One in Three 
Melanomas. Acta Derm Venereol. 2013;93(6):689-692. doi:10.2340/00015555-
1625. 
37.  St. Sauver JL, Warner DO, Yawn BP, et al. Why Patients Visit Their Doctors: 
Assessing the Most Prevalent Conditions in a Defined American Population. Mayo 
Clin Proc. 2013;88(1):56-67. doi:10.1016/j.mayocp.2012.08.020. 
38.  McCleskey PE. Clinic teaching made easy: A prospective study of the American 
Academy of Dermatology core curriculum in primary care learners. J Am Acad 
Dermatol. 2013;69(2):273-279.e1. doi:10.1016/j.jaad.2012.12.955. 
39.  Ferris L, Saul M, Lin Y, et al. Preliminary outcomes of a primary care-based skin 
cancer screening program. J Clin Oncol. 2016;34(suppl; abstr 1508). 
http://meetinglibrary.asco.org/content/168283-176. Accessed December 21, 2016. 
  
	  41 
CURRICULUM VITAE 
